One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial

What Was Tested

The paper reports a study of Exenatide and Insulin Glargine, published as a randomized controlled trial.

Traditional blood glucose-lowering agents do not sustain adequate glycemic control in most type 2 diabetic patients.

The researchers investigated the effects of 52 weeks of treatment with exenatide or insulin glargine followed by an off-drug period on hyperglycemic clamp-derived measures of beta-cell function, glycemic control, and body weight.

Who Took Part

The study group was 2 patients.

PubMed indexes the participants as middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized.

Because people in this Exenatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Additional end points included effects on glycemic control, body weight, and safety.

What Was Measured

Topics PubMed links to this paper include Arginine, Blood Glucose, Body Mass Index, C-Peptide, Diabetes Mellitus, Type 2, Exenatide and Glycated Hemoglobin.

What This Means in Plain Language

The paper is a randomized study of Exenatide and Insulin Glargine in 2 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2009 (Diabetes care), a journal based in United States.

More context: the Exenatide compound page and the Insulin Glargine compound page.